PubMed:26447154 JSON TXT

Annnotations TAB JSON ListView MergeView

Inflammaging

wangzhuo19_800_2

{"project":"wangzhuo19_800_2","denotations":[{"id":"T1","span":{"begin":479,"end":511},"obj":"DP"},{"id":"T2","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T3","span":{"begin":675,"end":679},"obj":"DP"},{"id":"T4","span":{"begin":974,"end":978},"obj":"DP"},{"id":"T5","span":{"begin":1293,"end":1297},"obj":"DP"},{"id":"T6","span":{"begin":1656,"end":1660},"obj":"DP"},{"id":"T7","span":{"begin":2466,"end":2470},"obj":"DP"},{"id":"T8","span":{"begin":2218,"end":2222},"obj":"DP"},{"id":"T9","span":{"begin":53,"end":71},"obj":"DP"},{"id":"T10","span":{"begin":0,"end":12},"obj":"CI"},{"id":"T11","span":{"begin":290,"end":302},"obj":"CI"},{"id":"T12","span":{"begin":1016,"end":1028},"obj":"CI"},{"id":"T13","span":{"begin":759,"end":771},"obj":"CI"},{"id":"T14","span":{"begin":2137,"end":2149},"obj":"CI"},{"id":"T15","span":{"begin":2372,"end":2384},"obj":"CI"},{"id":"T16","span":{"begin":2326,"end":2337},"obj":"CI"},{"id":"T17","span":{"begin":1862,"end":1874},"obj":"CI"},{"id":"T18","span":{"begin":1334,"end":1346},"obj":"CI"},{"id":"T19","span":{"begin":536,"end":548},"obj":"CI"},{"id":"T20","span":{"begin":1182,"end":1194},"obj":"CI"},{"id":"T21","span":{"begin":1468,"end":1480},"obj":"CI"},{"id":"T22","span":{"begin":2436,"end":2448},"obj":"CI"},{"id":"T23","span":{"begin":387,"end":399},"obj":"CI"},{"id":"T24","span":{"begin":220,"end":232},"obj":"CI"}],"text":"α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial.\nBACKGROUND: Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements.\nOBJECTIVE: Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins.\nDESIGN: A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h.\nRESULTS: Compared with healthy participants, those with MetS had lower (P \u003c 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: 2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein.\nCONCLUSIONS: At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. These findings support higher dietary α-tocopherol requirements for MetS adults. This trial was registered at www.clinicaltrials.gov as NCT01787591."}

Zierdiyeerkenaili_800_2

{"project":"Zierdiyeerkenaili_800_2","denotations":[{"id":"T1","span":{"begin":493,"end":511},"obj":"DP"},{"id":"T2","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T3","span":{"begin":675,"end":679},"obj":"DP"},{"id":"T4","span":{"begin":974,"end":978},"obj":"DP"},{"id":"T5","span":{"begin":1293,"end":1297},"obj":"DP"},{"id":"T6","span":{"begin":1656,"end":1660},"obj":"DP"},{"id":"T7","span":{"begin":2218,"end":2222},"obj":"DP"},{"id":"T8","span":{"begin":2466,"end":2470},"obj":"DP"},{"id":"T9","span":{"begin":53,"end":71},"obj":"DP"}],"text":"α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial.\nBACKGROUND: Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements.\nOBJECTIVE: Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins.\nDESIGN: A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h.\nRESULTS: Compared with healthy participants, those with MetS had lower (P \u003c 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: 2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein.\nCONCLUSIONS: At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. These findings support higher dietary α-tocopherol requirements for MetS adults. This trial was registered at www.clinicaltrials.gov as NCT01787591."}

chenxin_473849_800_3

{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":675,"end":679},"obj":"DP"},{"id":"T2","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T3","span":{"begin":974,"end":978},"obj":"DP"},{"id":"T4","span":{"begin":1293,"end":1297},"obj":"DP"},{"id":"T5","span":{"begin":1656,"end":1660},"obj":"DP"},{"id":"T6","span":{"begin":2218,"end":2222},"obj":"DP"},{"id":"T7","span":{"begin":2466,"end":2470},"obj":"DP"},{"id":"T8","span":{"begin":53,"end":71},"obj":"DP"},{"id":"T9","span":{"begin":493,"end":511},"obj":"DP"}],"text":"α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial.\nBACKGROUND: Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements.\nOBJECTIVE: Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins.\nDESIGN: A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h.\nRESULTS: Compared with healthy participants, those with MetS had lower (P \u003c 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: 2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein.\nCONCLUSIONS: At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. These findings support higher dietary α-tocopherol requirements for MetS adults. This trial was registered at www.clinicaltrials.gov as NCT01787591."}

yangbin123xm_800_3

{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":53,"end":71},"obj":"DP"},{"id":"T2","span":{"begin":493,"end":511},"obj":"DP"},{"id":"T3","span":{"begin":513,"end":517},"obj":"DP"},{"id":"T4","span":{"begin":675,"end":679},"obj":"DP"},{"id":"T5","span":{"begin":974,"end":978},"obj":"DP"},{"id":"T6","span":{"begin":1293,"end":1297},"obj":"DP"},{"id":"T7","span":{"begin":1656,"end":1660},"obj":"DP"},{"id":"T8","span":{"begin":2466,"end":2470},"obj":"DP"},{"id":"T9","span":{"begin":2218,"end":2222},"obj":"DP"}],"text":"α-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial.\nBACKGROUND: Increasing dietary fat intake is expected to improve α-tocopherol bioavailability, which could be beneficial for improving α-tocopherol status, especially in cohorts at high cardiometabolic risk who fail to meet dietary α-tocopherol requirements.\nOBJECTIVE: Our objective was to assess dose-dependent effects of dairy fat and metabolic syndrome (MetS) health status on α-tocopherol pharmacokinetics in plasma and lipoproteins.\nDESIGN: A randomized, crossover, double-blind study was conducted in healthy and MetS adults (n = 10/group) who ingested encapsulated hexadeuterium-labeled (d6)-RRR-α-tocopherol (15 mg) with 240 mL nonfat (0.2 g fat), reduced-fat (4.8 g fat), or whole (7.9 g fat) milk before blood collection at regular intervals for 72 h.\nRESULTS: Compared with healthy participants, those with MetS had lower (P \u003c 0.05) baseline plasma α-tocopherol (μmol/mmol lipid) and greater oxidized low-density lipoprotein (LDL), interleukin (IL)-6, IL-10, and C-reactive protein. Regardless of health status, d6-α-tocopherol bioavailability was unaffected by increasing amounts of dairy fat provided by milk beverages, but MetS participants had lower estimated d6-α-tocopherol absorption (±SEM) than did healthy participants (26.1% ± 1.0% compared with 29.5% ± 1.1%). They also had lower plasma d6-α-tocopherol AUC from 0 to 72 h, as well as maximal concentrations (Cmax: 2.04 ± 0.14 compared with 2.73 ± 0.18 μmol/L) and slower rates of plasma disappearance but similar times to Cmax. MetS participants had lower d6-α-tocopherol AUC from t = 0-12 h (AUC0- t final) in lipoprotein fractions [chylomicron, very-low-density lipoprotein (VLDL), LDL, high-density lipoprotein]. Percentages of d6-α-tocopherol AUC0- t final in both the chylomicron (r = -0.46 to -0.52) and VLDL (r = -0.49 to -0.68) fractions were inversely correlated with oxidized LDL, IL-10, IL-6, and C-reactive protein.\nCONCLUSIONS: At dietary intakes equivalent to the Recommended Dietary Allowance, α-tocopherol bioavailability is unaffected by dairy fat quantity but is lower in MetS adults, potentially because of greater inflammation and oxidative stress that limits small intestinal α-tocopherol absorption and/or impairs hepatic α-tocopherol trafficking. These findings support higher dietary α-tocopherol requirements for MetS adults. This trial was registered at www.clinicaltrials.gov as NCT01787591."}